Supplementary material should be supplied as a single pdf labeled Appendix. The Appendix includes a table of content on the first page, all figures and their legends. Please follow the nomenclature Appendix Figure Sx throughout the text and also label the figures according to this nomenclature. For more details please refer to our guide to authors. Important: All materials and methods should be included in the main manuscript file.
Regarding data quantification and statistics, can you please specify the number "n" for how many experiments were performed, the bars and error bars (e.g. SEM, SD) and the test used to calculate pvalues in the respective figure legends? This information must be provided in the figure legends. Please also include scale bars in all microscopy images.
We now strongly encourage the publication of original source data with the aim of making primary data more accessible and transparent to the reader. The source data will be published in a separate source data file online along with the accepted manuscript and will be linked to the relevant figure.
If you would like to use this opportunity, please submit the source data (for example scans of entire gels or blots, data points of graphs in an excel sheet, additional images, etc.) of your key experiments together with the revised manuscript. Please include size markers for scans of entire gels, label the scans with figure and panel number, and send one PDF file per figure or per figure panel. I look forward to seeing a revised version of your manuscript when it is ready. Please let me know if you have questions or comments regarding the revision.
REFEREE REPORTS
Referee #1:
Overall interesting paper with several clear colonization phenotypes. In the results text it is not clear if Figure 3C is in SPF or gnotobiotic animals.
The ability of BF9343_1927 to provide immunity to T6SS is demonstrated in the case of cocolonization in Figure 2 , but is not shown in any of the cases of sequential colonization. This data is important because it is the main evidence that the reason the mutant has colonization defects is because of its inability to inject an effector.
Can one observe killing in vitro that supports colonization data? Currently in the paper it seems there are no examples of this, as in cases where T6SS is shown to kill B. theta and B. vulgatus, there is no matching colonization phenotype. Does it kill other strains in vitro? If not, is it because of a lack of expression? Is T6SS induced in vivo? Is it induced by the presence of an invader in vivo?
This study demonstrates the role of type vi secretion in host colonization resistance against pathogenic and non-pathogenic B. fragilis strains. It also identifies a putative type Vi secretion immunity protein in B. fragilis. Very interesting/solid work. I only have a few minor concerns: Figure 3 A and B; it seems that strain E1 colonizes to the same levels as strain N1 when introduced together. It is confusing that only N1 is labeled. Also, how this compares with experiment presented in figure 2B where co-colonization of wild type N1 and E1 strains results in significantly lower levels of colonization of E1.
It was not clear how levels strains were quantified in invasion experiments where the same strain was introduced.
Referee #3:
In this manuscript Hecht et al. very elegantly examine the role of Bacteroides fragilis type VI secretion system in a competitive setting in the mammalian gut. In particular they looked at the commensal B.f. (N1) activity against the toxigenic B.f. (E1) when the commensal E1 either expresses or not the tssC effector protein. Also, they describe the presence of a possible gene encoding for an immunity protein in the N1 genome, which when expressed in E1 confers the ability to E1 to persist in the gut. They further show that the T6SS is important for developing colonization resistance against exposure of E1 when mice were previously colonized with N1. Moreover, they explored how the T6SS would affect a broader community of Bacteroidetes in a competitive setting, highlighting the complexities of microbe-microbe interactions in vivo.
Overall, this manuscript provides strong evidence for the importance of T6SS in competition within closely related bacteria species and strains. Most importantly, this work highlights the significance of investigating the role of bacterial competition strategies in a complex environment such as the mammalian gut. I have a few suggestions below:
1) The authors speculate that niches that are spatially distinct between different Bac strains could explain the differences in the T6SS effect against diverse strains (as shown in Figure 3 and S4). It would be nice if the authors could visualize the differential distributions of these communities, if tissue samples are available and specific FISH probes can be used.
2) Some questions that the authors may want to consider are the following: is there a differential timing expression of T6SS? Is the T6SS expression in vivo depended upon the presence of a competitor? What happens in more complex communities?
3) The therapeutic side of administration of a commensal B. f. to exclude the toxigenic Bac is very interesting and is potentially clinically relevant. Is there a mouse model in which the authors could test this idea further? We thank the referees for their insightful and helpful comments, which have enabled significant improvements to our manuscript regarding the competition between non-toxigenic and enterotoxigenic strains of Bacteroides fragilis. We now find type VI secretion-dependent competition between B. fragilis strains in vitro that is congruent with the in vivo data shown in the initial submission, further illustrating the direct interaction between non-toxigenic and toxigenic strains. In the initial submission, we identified an immunity gene that, when heterologously expressed in enterotoxigenic B. fragilis, protects from type VI secretion killing in vivo. To further demonstrate that this effector-immunity pair is critical for this interaction, we now show that mutation of the cognate effector in the non-toxigenic strain phenocopied the type VI secretion mutant. Finally, we now demonstrate that the non-toxigenic strain acts as a probiotic through type VI secretion, protecting the host from the enterotoxigenic strain by reducing exposure to toxin and decreasing intestinal damage in a mouse model of colitis. Given the data added to the manuscript, we have changed the title accordingly to more accurately reflect the central findings of the work.
Referee #1:
Overall interesting paper with several clear colonization phenotypes.
Hecht et al. Reply: We appreciate the referee's interest in our study. Figure 3C is in SPF or gnotobiotic animals.
In the results text it is not clear if
Hecht et al. Reply: Figure 3C was performed in SPF mice, which is now noted in the figure legend and the results section.
The ability of BF9343_1927 to provide immunity to T6SS is demonstrated in the case of cocolonization in Figure 2, but is not shown in any of the cases of sequential colonization. This data is important because it is the main evidence that the reason the mutant has colonization defects is because of its inability to inject an effector.
Hecht et al. Reply: To provide further evidence for effector injection as a mechanism of strain competition, we now show that mutation of the cognate effector of BF9343_1927, BF9343_1928 (now named 'Bte2' in recent publication) [1, 2] causes a loss of E1 killing both in vitro and in vivo (Figs 2C and E and EV1I). We additionally find that heterologous expression of BF9343_1927 (now named 'Bti2a') protects E1 in vitro as support for the in vivo data presented upon initial submission ( Fig EV1I) . This is further confirmed by recent work demonstrating the importance of this effector-immunity pair in B. fragilis strain competition [1, 2] . We therefore conclude that the effector Bte2 is injected by N1 through T6S into E1 both in vitro and in vivo, causing a competitive phenotype that can be mitigated upon heterologous expression of the immunity protein Bti2a in E1.
At present, we have not explored the role of Bti2a in sequential colonization. N1 is the only strain in our studies encoding Bte2/Bti2a, however this strain does not exclude E1 from secondary colonization (Fig 3A and B) . Therefore, the sequential model is not optimal for testing the involvement of this effector-immunity pair in strain competition.
Can one observe killing in vitro that supports colonization data? Currently in the paper it seems there are no examples of this, as in cases where T6SS is shown to kill B. theta and B. vulgatus, there is no matching colonization phenotype. Does it kill other strains in vitro? If not, is it because of a lack of expression? Is T6SS induced in vivo? Is it induced by the presence of an invader in vivo?
Hecht et al. Reply: In our revised manuscript, we present evidence of in vitro killing that is congruent with co-colonization. Plate competition assays produce significant killing of E1 by N1, which is relieved upon mutation of the T6SS (Fig EV1I) . Moreover, deletion of the effector Bte2 in N1 or heterologous expression of Bti2a in E1 similarly reduces the killing phenotype. Thus, in vitro and in vivo competition between N1 and E1 are consistent with one another, further emphasizing the importance of T6S and this effector-immunity pair. This data suggests that T6S is active both in vitro and in vivo, supported by work published since our initial submission [1, 2] . The conditions of T6SS expression have not been explored in Bacteroides. Induction of T6S in the presence of a T6S-encoding competitor is a known phenomenon in Pseudomonas aeruginosa [1] [2] [3] , but remains to be studied in B. fragilis. While we find these topics to be of great interest, we believe they fall outside the scope of the current manuscript. Hecht et al. Reply: We thank the referee for her/his interest in our work and apologize for the confusion regarding Figure 3A and B. In this experiment, primary colonization with N1 (closed squares, upper lines) eliminates secondary challenge with the same N1 strain (closed squares, lower lines). However, primary colonization with N1 (open squares, upper lines) is unable to completely eliminate E1 secondary challenge (open squares, lower lines). In this experiment, both sets of mice are initially colonized by N1, thus only N1 is labeled in the top lines. To be clear, in this experiment there is no co-colonization of N1 and E1; the inoculation of the two strains is separated by time. Thus, these data are not contradictory with Figure 2B . To better convey this point, Figure 3A and B have been slightly altered, labeling the arrow at the point of inoculation with the strains used.
Hecht et al. Reply: Sequential colonization using the same challenge strain as the primary colonizing strain was accomplished through expression of differential plasmid-encoded antibiotic resistance markers. The utility of this technique has been previously published [4] and was confirmed in our work through PCR-based genomic identification of the primary and secondary strains (Appendix Figure S1 ). This technique is noted in the revised text in the results and methods sections. Hecht et al. Reply: We thank the referee for her/his detailed analysis of our studies. We concur that imaging of spatially distinct niches would be of considerable interest and represents a substantial advance in the field, however, technology for differential detection of strains in vivo is currently lacking. While FISH has been used successfully to image B. fragilis, this was accomplished with FISH probes against 16S rRNA [5] ; the similarity in sequence between B. fragilis strains in this study makes this approach intractable. We have attempted to image B. fragilis through overexpression of fluorescent reporters, but to date, these have failed to produce a significant signal. Future work to develop such technology will be required to successfully accomplish these studies.
2) Some questions that the authors may want to consider are the following: is there a differential timing expression of T6SS? Is the T6SS expression in vivo depended upon the presence of a competitor? What happens in more complex communities?
Hecht et al. Reply: We likewise find interest in possible timing and induction conditions of T6S during colonization and in complex communities. T6SSs characterized in Vibrio cholerae and P. aeruginosa require specific environmental conditions for optimal transcription, and the presence of competitors enhances firing of the system [3] . Our work demonstrates that the B. fragilis T6SS is active both in vitro and in vivo. Recent studies show that additional complexity in bacterial communities in vivo dampen the number of B. fragilis competition events as a result of T6S [1] . Future work will be required to determine the role of T6SS expression in these contexts and to identify induction conditions.
3) The therapeutic side of administration of a commensal B. f. to exclude the toxigenic Bac is very interesting and is potentially clinically relevant. Is there a mouse model in which the authors could test this idea further?
Hecht et al. Reply: We thank the referee for her/his insightful comments on the potential therapeutic implications of the work. In the revised manuscript, we have taken four approaches to determine the health impact of competition between non-toxigenic and toxigenic B. fragilis strains. First, we determined the quantity of bft mRNA present in the feces during competition of E1 with N1 WT or N1 ΔtssC (Fig 5A) . We find that N1 WT is able to significantly reduce the toxin expressed relative to the T6S-deficient mutant. Second, to determine if this increased toxin expression manifests as a concomitant host response, we examined the quantity of anti-BFT IgG in the mouse serum after colonization (Fig 5B) . We show that N1 WT significantly decreases the anti-BFT IgG compared to N1 ΔtssC, suggesting that the host exposure to toxin is modulated by T6S. Third, using a mouse model in which susceptibility to colitis is elicited by dextran sodium sulfate (DSS) treatment, we examined the gross intestinal morphology after infection with E1-only or competition with N1 ( Figs  5C and EV4A) . Cecum size and architecture changed dramatically in the E1-only inoculated mice, demonstrating shrinking, overt blood and decreased weight. These signs of inflammatory injury were ameliorated by competition with N1 WT. While N1 ΔtssC provided partial relief from E1-induced damage, cecal weight remained significantly lower than N1 WT, showing that T6S is partially required for protection. Fourth, we examined the histopathology of the ceca and colons from these mice and found that while the E1-only condition produced significant ulceration in both tissues, including loss of crypts, denudation of the epithelium and inflammatory infiltrates, competition with N1 WT completely restored these phenotypes to normal (Figs 5D-F and EV4B-D). Therefore, we conclude that B. fragilis strain competition provides significant beneficial effects via suppression of host exposure to BFT, and may provide a framework for targeted therapeutic probiotics. Associated with these changes, the following text was added to the results section:
Results: ETBF colonization is associated with IBD and colitis in humans, experimentally validated in mouse model systems [6] [7] [8] . We hypothesized that strain competition may favorably alter the health of the host through reduced exposure to toxigenic organisms. Co-colonization of E1 with WT N1 reduced BFT transcript present in the feces by approximately 100-fold relative to competition with N1 ΔtssC, congruent with the difference in E1 fecal CFU (Fig 5A; compare to Fig 1A, B and  D) . A concomitant decrease in mouse anti-BFT serum IgG was observed, reminiscent of observations in ETBF-exposed humans (Fig 5B) [8] . Infection of mice with ETBF exacerbates a BFT-dependent, IBD-like colitis induced by dextran sodium sulfate (DSS) administration [7] . Colonization with E1 in this model causes significant intestinal injury, indicated by the presence of visible blood in the ceca, substantial tissue contraction and reduced cecal weight relative to shaminoculated animals (Figs 5C and EV4A). We hypothesized that N1 competition would reduce the disease burden in this model, consistent with suppression of the E1 burden by WT N1 (Fig 1A) . Indeed, co-colonized mice did not exhibit evidence of cecal injury (Figs 5C and EV4A). Competition with N1 ΔtssC also reduced inflammation associated with E1 colonization, but not as effectively as N1 WT co-colonization, indicating that T6S is required for full protection (Fig 5C) . Examination of both cecal and colonic histopathology revealed severe ulcerations in mice monocolonized with E1, demonstrated by loss of crypts, epithelial denudation, and the presence of inflammatory cell infiltration ( Figs 5D-F and EV4B-D) . Competition of E1 with N1 WT provided complete protection from damage throughout the length of the cecum and colon. These data demonstrate that the N1 T6SS affords the host significant protection from E1 colonization and BFTinduced injury. Thank you for the submission of your revised manuscript to our editorial offices. We have now received the enclosed reports on it. As you will see, all three referees find the manuscript suitable for publication in EMBO reports. Before we can proceed with the formal acceptance of your manuscript, I would like to ask you for some very minor revisions.
For a short report, we usually require that the results part and the discussion are combined to one section (Results and Discussion). Could you please do so? We also require a conflict of interest statement, which should be included after the acknowledgements. Please also insert page numbers to your manuscript. Finally, it appears that the third panel (N1 WT, E1 WT) of Fig. EV4A is cut at the right end. Maybe you can replace this?
I look forward to seeing a revised version of your manuscript when it is ready. Please let me know if you have questions or comments regarding the revision.
REFEREE REPORTS
The authors have thoughtfully and thoroughly addressed my concerns. I have no more comments and look forward to seeing the paper published.
Referee #2: my concerns were addressed.
I confirm my very positive opinion on this work. The authors have also provided additional data that further improved the manuscript. This is a novel and important study, which will be of great interest to the field. Thank you for the email -we are delighted on the favorable reviews of our paper! I have attached the revised word doc as you note below, as well as the revised figure. the exact sample size (n) for each experimental group/condition, given as a number, not a range; a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
No investigator blinding was used. Manuscript draft P. 13, Methods section Manuscript draft P. 13, Methods section definitions of statistical methods and measures:
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified Please fill out these boxes ê (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name). 
YOU MUST COMPLETE ALL CELLS WITH A PINK BACKGROUND ê

